drugset / Trial / NCT01622504

Naloxone Nasal Spray Pharmacokinetic Study

NCT01622504

Phase 1 Unknown 6 enrolled Mitovie Pharma Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to compare the pharmacokinetics of naloxone when administered as the Mitovie nasal spray (Test Product) and as a solution for injection (Comparator Product) administered intranasally using a mucosal atomization device (MAD).

Timeline

Start
2012-06
Primary completion
2012-07
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject MVP005 Unknown 2 mg Intranasal
Subject MVP005 Unknown 4 mg Intranasal
Comparator Naloxone Small molecule 2 mg Intranasal